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TAmong the primary objectives of the American Society
or Blood and Marrow Transplantation are to:
Deﬁne commonly accepted medical practice
Develop standards of medical care for autologous and
allogeneic transplants
Provide recommendations and guidelines about the role
of transplantation as a therapeutic approach for reim-
bursement by third-party payers
o this end, in 1999 the Society began the development of
vidence-based reviews of the scientiﬁc and medical litera-
ure to document when blood and marrow transplantation is
ndicated in the treatment of selected diseases.
oals
The goals of the evidence-based reviews are to:
Assemble and critically evaluate all of the evidence re-
garding the role of cytotoxic therapy with hematopoi-
etic stem cell transplantation in the treatment of each
disease selected for review
Make treatment recommendations based on the avail-
able evidence
Identify discrepancies in study design or methodology
among published studies that may impact the quality of
the evidence
Identify needed areas of additional study
uidelines
The following guidelines are offered for the role of stem
ell transplantation as therapy for diffuse large cell B-cell
on-Hodgkin’s lymphoma (DLCL) and are based on con-
ensus reached by an expert panel following an evidence-
ased review of the literature. Treatment recommendations
ere made by disease response and, where available, Inter-
ational Prognostic Index (IPI) risk.
Expert panel members and authors of the review are: Theresa Hahn,
hD, Roswell Park Cancer Institute, Buffalo, NY; Steven N. Wolff,
D, Vanderbilt University, Nashville, TN, Myron Czuczman, MD,
oswell Park Cancer Institute, Buffalo, NY; Richard I. Fisher, MD,
ardinal Bernardin Cancer Center, Loyola University, Chicago, IL;
illard M. Lazarus, MD, Comprehensive Cancer Center, University
ospitals of Cleveland, Case Western Reserve University, Cleveland,
H; Philip L.McCarthy,MD, Roswell Park Cancer Institute, Buffalo,
Y; Julie Vose, MD, University of Nebraska Medical Center, Omaha,
E; LisaWarren, Cure for Lymphoma Foundation,NewYork,NY; and
ichard Watt, MD, United Resource Networks, Minneapolis, MN.
Reference: Hahn T, Wolff SN, Czuczman M, et al. The role of
ytotoxic therapy with hematopoietic stem cell transplantation in the
herapy of diffuse large cell B-cell non-Hodgkin’s lymphoma: an evi-
ence-based review. Biol Blood Marrow Transplant. 2001;7:308-331.B&MT. Stem cell transplantation in the treatment of DLCL is
more effective than conventional chemotherapy and is
the recommended treatment for the following:
● First chemotherapy-sensitive relapse
● First complete remission in high/intermediate-high
risk IPI patients
● As high-dose sequential therapy in intermediate-
high/high risk IPI untreated patients
. Stem cell transplantation is not more effective than con-
ventional chemotherapy and is not recommended for the
following:
● First complete remission in low/intermediate-low
risk IPI patients
● After abbreviated induction therapy: 6 or fewer cy-
cles of cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP) or 12 or fewer cycles of
methotrexate, doxorubicin, cyclophosphamide, vin-
cristine, prednisone, and bleomycin (MACOP-B) or
etoposide, doxorubicin, cyclophosphamide, vincris-
tine, prednisone, and bleomycin (VACOP-B)
. No treatment recommendations are made for indications
which have not been evaluated adequately but are rec-
ommended for comparative study, including:
● Chemotherapy-resistant relapse/primary refractory
disease
● First partial remission after full-course induction
therapy
● As high-dose sequential therapy in low/intermediate-
low risk IPI untreated patients
. Autologous stem cell transplantation is currently the
standard of care and is preferred over allogeneic stem cell
transplantation. Studies are ongoing, however, to further
evaluate the role of allogeneic transplant.
. Autologous peripheral blood stem cell transplantation
(PBSCT) is preferred over autologous bone marrow
transplantation.
. No treatment recommendations are made for transplanta-
tion techniques that have not been evaluated adequately but
are recommended for comparative study, including:
● Double/tandem stem cell transplantation
● Myeloablative allogeneic stem cell transplantation
● Nonmyeloablative allogeneic stem cell transplanta-
tion
● Purging
● Stem cell mobilization methods
● Conditioning regimens
—Adopted by the ASBMT Executive Committee
on April 17, 2003
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